{Reference Type}: Journal Article
{Title}: Prescribing patterns and persistence of biological therapies for psoriasis management: a retrospective cohort study from Saudi Arabia.
{Author}: Alamer A;Alyazidi W;Aldosari S;Mobarki F;Almakki S;Alahmari A;Alomar M;Almalki Z;Alkaff T;Fazel M;
{Journal}: J Dermatolog Treat
{Volume}: 35
{Issue}: 1
{Year}: 2024 Dec
{Factor}: 3.23
{DOI}: 10.1080/09546634.2024.2386973
{Abstract}: <B>UNASSIGNED: </B>Biological therapies are effective for psoriasis, but patient responses vary, often requiring therapy switching or discontinuation.<BR><B>UNASSIGNED: </B>To identify physicians' prescribing patterns of biological therapies at a referral tertiary center in Saudi Arabia and assess the probability of biologic persistence following treatment initiation.<BR><B>UNASSIGNED: </B>We conducted a retrospective study of biologic-naïve adult psoriasis patients who initiated therapy from October 2013 to July 2022 in Dammam. Descriptive statistics and a Kaplan-Meier analysis evaluated treatment persistence at 6, 12, 24, and 36 months.<BR><B>UNASSIGNED: </B>A total of 151 patients received adalimumab (n = 89), etanercept (n = 17), risankizumab (n = 30), ustekinumab (n = 14), and ixekizumab (n = 1). At 6 months, all therapies demonstrated 100% persistence. At 12 months, persistence was highest for ustekinumab (100%) and lowest for etanercept (88.2%). At 24 months, ustekinumab maintained 100% persistence, followed by risankizumab (96.6%), adalimumab (94.3%), and etanercept (76.4%). At 36 months, risankizumab had the highest persistence (96.6%), followed by adalimumab (83.1%), ustekinumab (78%), and etanercept (70.6%). The most common reasons for discontinuation were lack of effectiveness and intolerability.<BR><B>UNASSIGNED: </B>This study shows changing psoriasis treatment patterns with new therapies. Risankizumab demonstrated high long-term persistence, while etanercept and ustekinumab showed declining persistence, suggesting evolving treatment considerations.